Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
214 hedge funds and large institutions have $2.84B invested in Blueprint Medicines in 2023 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 92 increasing their positions, 60 reducing their positions, and 33 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 60
1.19% more ownership
Funds ownership: 104.12% → 105.31% (+1.2%)
4% more capital invested
Capital invested by funds: $2.73B → $2.84B (+$116M)
4% less funds holding
Funds holding: 222 → 214 (-8)
15% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 33
28% less call options, than puts
Call options by funds: $15.8M | Put options by funds: $21.8M
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$29.2M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$18.5M |
| 3 |
BlackRock
New York
|
+$15.7M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$15M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$9.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
-$36.4M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$23.2M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
-$21M |
| 4 |
Millennium Management
New York
|
-$12.2M |
| 5 |
NI
Nextech Invest
Zurich,
Switzerland
|
-$8.25M |
BPMC Hedge Fund Activity: Q1 2023 in Review
214 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q1 2023, worth a combined $2.84B — up 4.2% from $2.73B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of BPMC and 28 opened new positions — a net loss of 5 holders — while 60 trimmed existing stakes and 92 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $29.2M. The largest seller was Casdin Capital, cutting an estimated $36.4M.
- 214 institutional investors held Blueprint Medicines (BPMC) as of Q1 2023, down from 222 in Q4 2022.
- Funds reported $2.84B of Blueprint Medicines stock for Q1 2023, up 4.2% quarter-over-quarter.
- 28 funds opened new Blueprint Medicines positions in Q1 2023 and 33 closed out, a net change of -5 holders.
- The largest Blueprint Medicines buyer in Q1 2023 was T. Rowe Price Associates, an estimated $29.2M added.
- The largest Blueprint Medicines seller in Q1 2023 was Casdin Capital, an estimated $36.4M sold.
Based on aggregated 13F filings for Q1 2023.